S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in
NYSE:GSK

GlaxoSmithKline Stock Forecast, Price & News

$38.47
+0.31 (+0.81 %)
(As of 01/15/2021 08:00 PM ET)
Add
Compare
Today's Range
$38.21
Now: $38.47
$38.66
50-Day Range
$36.09
MA: $37.24
$38.34
52-Week Range
$31.43
Now: $38.47
$48.25
Volume223,133 shs
Average Volume4.04 million shs
Market Capitalization$96.50 billion
P/E Ratio11.84
Dividend Yield5.30%
Beta0.67
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Merck KGaA; Lyell Immunopharma; CEPI; Innovax and Xiamen University; VBI; Viome; Sanofi SA; CureVac; and research collaboration with Sengenics focusing on immunology. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
GlaxoSmithKline logo

MarketRank

Overall MarketRank

1.44 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 3.3Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone44-20-8047-5000
Employees99,437

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$43.10 billion
Cash Flow$4.43 per share
Book Value$9.40 per share

Profitability

Net Income$5.93 billion

Miscellaneous

Outstanding Shares2,508,520,000
Market Cap$96.50 billion
Next Earnings Date2/3/2021 (Estimated)
OptionableOptionable
$38.47
+0.31 (+0.81 %)
(As of 01/15/2021 08:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GSK News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











GlaxoSmithKline (NYSE:GSK) Frequently Asked Questions

How has GlaxoSmithKline's stock been impacted by COVID-19?

GlaxoSmithKline's stock was trading at $39.87 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GSK stock has decreased by 3.5% and is now trading at $38.47.
View which stocks have been most impacted by COVID-19
.

Is GlaxoSmithKline a buy right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last year. There are currently 2 sell ratings, 5 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GlaxoSmithKline stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.
View analyst ratings for GlaxoSmithKline
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than GlaxoSmithKline?

Wall Street analysts have given GlaxoSmithKline a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but GlaxoSmithKline wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is GlaxoSmithKline's next earnings date?

GlaxoSmithKline is scheduled to release its next quarterly earnings announcement on Wednesday, February 3rd 2021.
View our earnings forecast for GlaxoSmithKline
.

How were GlaxoSmithKline's earnings last quarter?

GlaxoSmithKline plc (NYSE:GSK) announced its quarterly earnings results on Wednesday, October, 28th. The pharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.14. The pharmaceutical company earned $11.17 billion during the quarter, compared to analyst estimates of $11.27 billion. GlaxoSmithKline had a return on equity of 29.60% and a net margin of 18.50%.
View GlaxoSmithKline's earnings history
.

How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline?

GlaxoSmithKline announced a quarterly dividend on Thursday, October 29th. Shareholders of record on Friday, November 13th will be given a dividend of $0.4959 per share on Thursday, January 14th. This represents a $1.98 dividend on an annualized basis and a dividend yield of 5.16%. The ex-dividend date of this dividend is Thursday, November 12th. This is a boost from GlaxoSmithKline's previous quarterly dividend of $0.49.
View GlaxoSmithKline's dividend history
.

Is GlaxoSmithKline a good dividend stock?

GlaxoSmithKline pays an annual dividend of $2.04 per share and currently has a dividend yield of 5.30%. GSK has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. GlaxoSmithKline does not yet have a strock track record of dividend growth. The dividend payout ratio of GlaxoSmithKline is 64.35%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, GlaxoSmithKline will have a dividend payout ratio of 66.23% next year. This indicates that GlaxoSmithKline will be able to sustain or increase its dividend.
View GlaxoSmithKline's dividend history.

Who are some of GlaxoSmithKline's key competitors?

What other stocks do shareholders of GlaxoSmithKline own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GlaxoSmithKline investors own include AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Cisco Systems (CSCO), AbbVie (ABBV), Intel (INTC), Gilead Sciences (GILD), The Walt Disney (DIS) and NVIDIA (NVDA).

Who are GlaxoSmithKline's key executives?

GlaxoSmithKline's management team includes the following people:
  • Ms. Emma N. Walmsley, CEO & Director (Age 51)
  • Mr. Iain James Mackay, CFO & Exec. Director (Age 59)
  • Dr. Hal V. Barron, Chief Scientific Officer, Pres of R&D and Director (Age 58)
  • Ms. Karenann K. Terrell, Chief Digital & Technology Officer (Age 60)
  • Ms. Sarah Elton-Farr, Head of Investor Relations
  • Mr. Nick Hirons, Sr. VP of Global Ethics & Compliance
  • Mr. James Ford, Sr. VP & Gen. Counsel
  • Ms. Sally Jackson, Sr. VP of Global Communications & CEO Office
  • Ms. Diana Conrad, Sr. VP of HR
  • Mr. David Simon Redfern, Chief Strategy Officer (Age 55)

What is GlaxoSmithKline's stock symbol?

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

Who are GlaxoSmithKline's major shareholders?

GlaxoSmithKline's stock is owned by a variety of institutional and retail investors. Top institutional investors include Douglas Lane & Associates LLC (0.05%), Jacobs & Co. CA (0.01%), Holloway Wealth Management LLC (0.00%), Signature Wealth Management Group (0.00%), Old Port Advisors (0.00%) and Advisors Management Group Inc. ADV (0.00%).
View institutional ownership trends for GlaxoSmithKline
.

Which major investors are selling GlaxoSmithKline stock?

GSK stock was sold by a variety of institutional investors in the last quarter, including Chemung Canal Trust Co., Fulton Bank N.A., City Holding Co., Raymond James Trust N.A., Boltwood Capital Management, Holloway Wealth Management LLC, Patriot Financial Group Insurance Agency LLC, and Gofen & Glossberg LLC IL.
View insider buying and selling activity for GlaxoSmithKline
or view top insider-selling stocks.

Which major investors are buying GlaxoSmithKline stock?

GSK stock was acquired by a variety of institutional investors in the last quarter, including Douglas Lane & Associates LLC, Jacobs & Co. CA, Bonness Enterprises Inc., Signature Wealth Management Group, Thomasville National Bank, Kovack Advisors Inc., Brookstone Capital Management, and Weather Gauge Advisory LLC.
View insider buying and selling activity for GlaxoSmithKline
or or view top insider-buying stocks.

How do I buy shares of GlaxoSmithKline?

Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is GlaxoSmithKline's stock price today?

One share of GSK stock can currently be purchased for approximately $38.47.

How big of a company is GlaxoSmithKline?

GlaxoSmithKline has a market capitalization of $96.50 billion and generates $43.10 billion in revenue each year. The pharmaceutical company earns $5.93 billion in net income (profit) each year or $3.17 on an earnings per share basis. GlaxoSmithKline employs 99,437 workers across the globe.

What is GlaxoSmithKline's official website?

The official website for GlaxoSmithKline is www.gsk.com.

How can I contact GlaxoSmithKline?

GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS. The pharmaceutical company can be reached via phone at 44-20-8047-5000 or via email at [email protected]

This page was last updated on 1/18/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.